How to locate and prescribe Emgality using the Electronic Media Record (EMR) system

Magnifying glass icon

1. Search for "Emgality"


EMR screen icon

2. In the EMR system, select the formulation for your patient's diagnosis1

Formulation for Migraine

Formulation for Migraine
Pack Size
NDC

Prefilled pen:
120 mg/mL single-dose

Pack size: Carton of 1 NDC: 0002-1436-11

Prefilled pen:
120 mg/mL single-dose

Pack size: Carton of 2 NDC: 0002-1436-27

Prefilled syringe:
120 mg/mL single-dose

Pack size: Carton of 1 NDC: 0002-2377-11

Prefilled syringe:
120 mg/mL single-dose

Pack size: Carton of 2 NDC: 0002-2377-27

Formulation for episodic cluster headache

Formulation for episodic cluster headache
Pack Size
NDC

Prefilled syringe:
100 mg/mL single-dose

Pack size: Carton of 3 NDC: 0002-3115-09

Rx prescription icon

3. Prescribe the appropriate dose for your patient:

Emgality 120 mg monthly for migraine

Loading Dose

(Use only if the patient does not begin treatment with a Loading Dose Sample Kita in the office)

Dispense: 2 pens or syringes (120 mg each) at once with 0 refills

Maintenance Dose

(Use for all patients with migraine)

Dispense: 1 pen or syringe (120 mg) once monthly with 10 refills

aLoading dose kits (samples) are intended to establish tolerability and efficacy for a patient.

Emgality 300 mg monthly for episodic cluster headache

Recommended Dose

Sig: 3 consecutive 100 mg SC injections at start of cluster period and monthly until end of cluster period

Dispense: (3) 100 mg prefilled syringes with 3 refills

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Emgality savings card image

By using the Emgality Savings Card Program ("Card"), you attest that you meet the eligibility criteria, and you agree to comply with the terms and conditions described below:

Card Eligibility:

(1.) You have been prescribed Emgality consistent with FDA approved product labeling

(2.) You are enrolled in a commercial drug insurance plan

(3.) You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program.

(4.) You are a resident of the United States or Puerto Rico

(5.) You are 18 years of age or older

Card Terms and Conditions

For patients with commercial drug insurance coverage for Emgality: You must have commercial drug insurance that covers Emgality and a prescription consistent with FDA-approved product labeling to pay as little as $0 for a 1-month prescription fill of Emgality. Month is defined as 30-days. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and separate maximum annual savings of up to $4,900 per calendar year. Subject to Lilly USA, LLC's ("Lilly") right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2024.

For patients with commercial drug insurance who do not have coverage for Emgality: You must have commercial drug insurance that does not cover Emgality and a prescription consistent with FDA-approved product labeling to pay as little as $0 for your first 1-month prescription fill of Emgality. Month is defined as 30-day. Card savings are subject to a maximum monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges for one 30-day supply of Emgality. Subject to Lilly's right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason, Card expires and savings end on 12/31/2024.

Additional Terms and Conditions

If you have an insurance plan that is participating in an alternate funding program ("AFP") (examples include, but are not limited to, ImpaxRX, Payer Matrix, SHARx, Script Sourcing, and Paydhealth) that requires you to apply to the Emgality Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of Emgality, you are not eligible for and are prohibited from using the Emgality Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly products from coverage contingent upon a member's use of Emgality Savings Card Program. You agree to inform Emgality Savings Card Program if you are or become a member of such an alternative funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum Card savings. Monthly and annual maximum savings are set at Lilly's sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for Emgality, only allows partial coverage for Emgality, removes coverage for Emgality and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of Emgality, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for Emgality. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. Card activation is required. No party may seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving Emgality. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are nontransferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. The Card is not insurance. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Eligibility criteria, and terms and conditions for the Emgality Savings Card Program may change from time to time; the most current version can be found at https://www.Emgality.com/savings. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly's right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly's sole discretion, without notice, and for any reason, the Card expires and savings end on 12/31/2024.

SC=subcutaneous.

References

  1. Emgality. Prescribing Information. Lilly USA, LLC.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache